{"id":4903,"date":"2019-10-09T17:01:51","date_gmt":"2019-10-09T15:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-gene-therapy-technologies-companies-markets-during-the-forecast-period-2018-2028-researchandmarkets-com\/"},"modified":"2019-10-09T17:01:51","modified_gmt":"2019-10-09T15:01:51","slug":"global-gene-therapy-technologies-companies-markets-during-the-forecast-period-2018-2028-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-gene-therapy-technologies-companies-markets-during-the-forecast-period-2018-2028-researchandmarkets-com\/","title":{"rendered":"Global Gene Therapy Technologies, Companies & Markets During the Forecast Period, 2018-2028 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Gene Therapy – Technologies, Markets & Companies”<\/a> report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s<\/strong>offering.\n<\/p>\n

<\/a><\/p>\n

\nGene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader. Gene therapy can now combined with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes a broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy reports written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic\n<\/p>\n

\nGene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression. Gene editing technologies such as CRISPR-Cas9 and CAR-T cell therapies are also included\n<\/p>\n

\nClinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.\n<\/p>\n

\nResearch and development are in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2016, over 2050 clinical trials were completed, were ongoing or had been approved worldwide. A breakdown of these trials is shown according to the geographical areas and applications.\n<\/p>\n

\nSince the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following the use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. Three gene medicines have been approved by the FDA. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including gene editing and germline gene therapy.\n<\/p>\n

\nThe markets for gene therapy have been difficult to estimate as there only a few approved gene therapy products Gene therapy markets are estimated for the years 2018-2028. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright. The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets\n<\/p>\n

\nBenefits of this report<\/strong>\n<\/p>\n